Compare LTC Properties Inc (LTC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Neurocrine Biosciences Inc — how do they compare? LTC Properties Inc trades at $42.46 (market cap $2.27B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.3× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.42% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LTC | NBIX | |
|---|---|---|
Market Cap | $2.27B | $14.36B |
Volume | 574,171 | 1,237,180 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $185.50 |
52-Week Low | $33.98 | $123.10 |
Typical Hold Time | 88 Days | 23 Days |
Enterprise Value | $3.01B | $14.37B |
Dividend Yield | 5.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.05, up 0.57% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The REIT demonstrates strong fundamentals with 38.93% net income margin and consistent dividend payments of $0.19 monthly. Recent strategic acquisitions totaling $360 million in SHOP properties signal aggressive growth plans while maintaining a manageable debt-to-asset ratio of 42.64%.
The outlook remains cautiously optimistic with a $49.67 consensus price target representing 18% upside potential. Key risks include rising interest rates impacting REIT valuations and execution challenges in the SHOP portfolio transition. Analyst sentiment is mixed with 32% buy ratings versus 55% hold, suggesting balanced risk-reward at current levels.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
